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Abstract
Response evaluation for cancer treatment consists primarily of clinical and radiological assessments. In addition, a limited
number of serum biomarkers that assess treatment response are available for a small subset of malignancies. Through recent
technological innovations, new methods for measuring tumor burden and treatment response are becoming available. By
utilization of highly sensitive techniques, tumor-specific mutations in circulating DNA can be detected and circulating tumor
DNA (ctDNA) can be quantified. These so-called liquid biopsies provide both molecular information about the genomic
composition of the tumor and opportunities to evaluate tumor response during therapy. Quantification of tumor-specific muta-
tions in plasma correlates well with tumor burden. Moreover, with liquid biopsies, it is also possible to detect mutations causing
secondary resistance during treatment. This review focuses on the clinical utility of ctDNA as a response and follow-up marker in
patients with non-small cell lung cancer, melanoma, colorectal cancer, and breast cancer. Relevant studies were retrieved from a
literature search using PubMed database. An overview of the available literature is provided and the relevance of ctDNA as a
response marker in anti-cancer therapy for clinical practice is discussed. We conclude that the use of plasma-derived ctDNA is a
promising tool for treatment decision-making based on predictive testing, detection of resistance mechanisms, and monitoring
tumor response. Necessary steps for translation to daily practice and future perspectives are discussed.
Keywords ctDNA .Mutation detection . Therapymonitoring . Follow-up . Driver mutations
1 Introduction
Response evaluation during anti-cancer therapy and follow-up
of patients with solid malignancies is currently primarily
based on radiological assessments according to response eval-
uation criteria in solid tumors (RECIST) [1]. Repeated
radiologic assessments are however time consuming, costly,
and increase the radiation burden for the patient. This is espe-
cially an issue in the context of the increasing number of long-
term cancer survivors due to new anti-cancer therapies.
Moreover, response evaluation based on radiologic assess-
ment is problematic with certain novel therapies. For example,
immunotherapy can cause pseudoprogression on radiologic
assessments as a result of influx of cytotoxic T-lymphocytes
[2] . I r radia t ion of high-grade gl ioma can cause
pseudoprogression on MRI in approximately one-third of
the patients [3]. And anti-VEGF therapy in colorectal cancer
can result in morphological changes such as altered delinea-
tion of the tumor, which predicts pathologic response and
overall survival better than does standard radiologic assess-
ment according to RECIST [4]. Finally, response assessment
can be difficult in certain settings regardless the therapy given.
In a bone-dominant disease such as prostate cancer and
hormone-positive breast cancer, response assessment is ham-
pered as bone lesions are considered non-evaluable by
RECIST [5].
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Novel therapies may not only cause difficulties with regard
to radiologic response assessment; these new treatments often
also aim at specific mutations (i.e., receptor tyrosine kinases
that are in a continuously activated state due to genetic aber-
rations). Therefore, for treatment decision-making up to date,
information about the genomic composition of the tumor le-
sions is crucial. Frequently, archival tissue is used for genomic
analysis of molecular aberrations. However, tumor character-
istics can change during the course of disease, such as devel-
opment of new mutations causing secondary resistance.
Repeated biopsies may be obtained, but this is not always
feasible, invasive, and not always representative of the whole
tumor burden due to sampling error and tumor heterogeneity
[6].
To circumvent the abovementioned limitations regarding
radiologic response assessment, as well as the need for up-
to-date information about molecular characteristics, there is a
clinical need for tumor-specific, highly sensitive, non-invasive
assays to determine the genomic composition of tumors and to
assess response accurately in solid malignancies.
2 Liquid biopsies
A potential method to obtain information about both the ge-
nomic composition of tumors and the tumor burden is through
detection and quantification of tumor DNA in plasma. Tumor
DNA can be identified by tumor-specific mutations that are
derived from circulating tumor cells (CTCs), tumor-derived
vesicles (exosomes), and nucleosome-bound tumor DNA that
is shed into the circulation during necrosis or apoptosis of
tumor cells [7–9]. Various methods to analyze and quantify
circulating tumor DNA (ctDNA) are available [10–12]. First-
generation sequencing methods are PCR-based techniques
such as droplet digital PCR (ddPCR) and breads, emulsifica-
tion, amplification and magnetics (BEAMing). Although
PCR-based techniques are limited by evaluating only a low
number of pre-specified mutations, the costs are relatively
low, an absolute number of aberrant copies per mL can be
provided, turnaround time is short, and sensitivity high.
More recently, next-generation sequencing (NGS) has been
developed, which can cover larger panels of selected genes/
mutations, whole-exome or even whole-genome sequencing.
Aside from its larger coverage when compared with ddPCR,
NGS also has the advantage that mutations do not need to be
pre-specified and therefore rare and novel mutations can be
detected. However, NGS is more costly, turnaround time is
longer, and sensitivity for mutations with low mutant allelic
frequency can be lower than with ddPCR [13].
As a method to quantify tumor burden, liquid biopsy has
the advantage over radiologic assessments that it may differ-
entiate between pseudoprogression and true progression, may
be used to evaluate response in settings in which radiologic
assessment is difficult (such as bone-dominant disease), and
can reduce radiation burden. As a method to obtain molecular
information, liquid biopsy has the advantage over biopsy-
driven genomic analysis that it is non-invasive, can provide
information about presence of various subclones, and gives
the opportunity to evaluate for secondary resistance mutations
during the course of disease. At this moment, the evidence to
support widespread use of ctDNA as a predictive or prognos-
tic marker in patients with solid malignancies is limited [14].
In this review, we summarize data on the application of
ctDNA analysis as a treatment response and follow-up marker
in patients with solid malignancies. We focus on non-small
cell lung carcinoma (NSCLC), melanoma, colorectal carcino-
ma (CRC), and breast cancer, given the specific driver muta-
tions that are often present and the availability of targeted
drugs.
3 Search strategy and quality of included
studies
A PubMed search was performed on January 1, 2019, using
the following syntax: (Oncology[tiab] OR Cancer* [tiab] OR
malignant[tiab] OR malignanc*[tiab] OR tumor[tiab] OR tu-
mour [tiab]) AND (DNA[tiab] OR “ Deoxyribonucleic
acid”[tiab] OR RNA[tiab] OR “Ribonucleic Acid”[tiab])
AND (Mutation*[tiab] OR Rearrange* [tiab]) AND
((“circulating”[tiab] OR ctDNA[tiab] OR cfDNA[tiab] OR
“liquid biopsy” OR “blood based” OR “Circulating tumor
cells”[tiab] OR “Circulating tumour cells”[tiab] OR
CTC[tiab] OR (“platelets”[tiab] OR Thrombocytes[tiab]))
AND (“humans”[MeSH Terms] AND English[lang]). The
search was limited to full articles, written in English. In total,
1057 articles were identified. Articles were screened on title,
abstract, and full text by PAB and TTW. Articles describing
sequential ctDNAmeasurements in human patients with solid
malignancies during systemic therapy were eligible. Studies
regarding the use of CTCs, exosomes, or other circulating
markers were excluded. Studies that investigated detection
of mutations in body fluids other than plasma were not within
the scope of this review.
Finally, 82 articles were eligible for this review (Table 1).
Of these, 26 articles provided detailed descriptions of individ-
ual cases or case series. No randomized clinical trials were
available. The remaining 56 articles consisted of studies that
evaluated the association of plasma ctDNA levels with re-
sponse rate (RR), progression-free survival (PFS), and/or
overall survival (OS). Relevant articles that not matched our
search criteria were occasionally added. All papers were clas-
sified for level of evidence following the rules as depicted by
the Oxford Centre for Evidence-Based Medicine [15]. Six
studies were classified as exploratory cohort studies with good














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 CRC studies). Fifty studies were non-consecutive studies
without consistently applied reference standards (3b) and 26
studies consisted of case reports or small series without poor
or non-independent reference standards (4, Table 1). Although
the largest study included 200 patients, most studies have low
patient numbers (range 1–200, median 14 patients).
3.1 Non-small cell lung cancer
The mutations of interest in most studies regarding NSCLC
are effecting the epidermal growth factor receptor (EGFR). Of
all EGFR mutations described in this review, 99% is found in
NSCLC. Other genes in which mutations were observed fre-
quently in NSCLC were TP53 and KRAS. Detection rate of
primary EGFR mutations in pre-treatment plasma ranged be-
tween 23 and 100%, highest detection was reached with PCR-
based methods compared with techniques based on (next-
generation) sequencing (median 79% vs 66.6%, respectively).
Thirty-three of the included 35 studies showed a positive
relation between treatment response and a decline in mutant
fraction after initiation of treatment. Disease progression
could be detected with ctDNA in 28 studies; 6 studies did
not have follow-up long enough for detection of progressive
disease and in one study, the decline in mutant ctDNA frag-
ments did not correspond with clinical disease status (Table 1)
[50].
Prolonged PFSwas observed for patients with undetectable
levels of ctDNA during treatment versus patients with persis-
tent detectable levels of ctDNA compared with baseline levels
[30, 33, 37]. A decrease or even disappearance of mutant
EGFR after start of treatment is a prognostic factor and indi-
cator of response and is associated with longer OS [21, 24, 47,
48, 51]. An increase of the EGFR activating mutation is sug-
gestive for therapy resistance and subsequent disease progres-
sion [16, 25, 32]. Smaller studies and case reports presented
similar results [27, 35, 44]. The use of ctDNA as an early
response marker is implicated by a longer OS in patients with
undetectable levels of ctDNA after 6 to 12 weeks of anti-
EGFR therapy compared with patients with detectable levels
of ctDNA after the same treatment period [30, 33, 37, 43, 46].
In patients with acquired EGFR tyrosine kinase inhibitor
(TKI)–resistant NSCLC, a rise of primary EGFR-mutated
DNA occurred simultaneously with the detection of new mu-
tations in the plasma in the majority of the tested patients
during treatment [28, 38, 41, 51]. Detection of the therapy-
resistant T790M mutation during treatment is suggestive for
disease progression and a worse OS [26, 34, 36, 42, 45, 49].
Secondary treatment-resistant mutations can also be used for
treatment monitoring but occur at lower frequencies than the
primary mutation and are therefore less suitable for detection
of disease progression [40]. Furthermore, these secondary mu-
tations could almost only be detected in patients with a prima-
ry EGFR mutation [18]. New uncommon mutations that
developed during treatment indicate clonal heterogeneity of
the tumor and could be detected using sequencing; this is
shown by the detection of a novel C797S or L747P mutation
and EML4-ALK gene translocation additional to the primary
EGFR exon 19– or T790M-resistant mutation during treat-
ment [17, 31, 41, 43].
Five studies reported an earlier detection of progressive
disease by ctDNA assessment as detected with conventional
radiological imaging [23, 29, 30, 40, 51].
KRAS mutations can also be used as circulating marker in
NSCLC patients treated with chemotherapy; patients with a
detectable KRAS mutation had worse overall survival com-
pared with patients with wild-type DNA (median 3.6 vs
8.4 months, respectively) [35]. A detectable KRAS mutation
also indicated resistance to treatment with EGFR-targeted
therapy in those patients (i.e., erlotinib or pertuzumab) [19,
39]. Of interest is the recent development of a specific
KRAS inhibitor that can target KRASG12C mutation [98].
When treatment with novel agents as nivolumab (anti-PD-
1) was initiated, a decrease in detectable specific mutations in
plasma within 8 weeks after start of therapy was observed in
responders (n = 11), while in non-responders (n = 5) a stable
or increasing level of plasma ctDNAwas detected [20, 22].
3.2 Cutaneous melanoma
Mutations in cutaneous melanoma were primarily observed in
v-Raf murine sarcoma viral oncogene homolog B (BRAF).
Detection rate of primary mutations in plasma ranged between
37 and 100% (median 70%); only one study used a sequenc-
ing approach to detect mutations (Table 1).
Two studies described a total of 31 patients with BRAF-
mutated melanoma treated with BRAF-inhibitors (BRAF-i)
alone or in combination with mitogen-activated protein kinase
inhibitors (MEK-i) [54, 58]. A disease control rate (DCR) of
75% was found in patients in whom mutation copy levels in
ctDNA decreased compared with a DCR of 18% in patients
with a stable or increasing level of ctDNA after 8 days of
therapy [54]. Patients with undetectable ctDNA levels after a
median of 13 days (range 6–40) of BRAF-i therapy had longer
PFS compared with patients with persistent detectable ctDNA
levels during therapy (n = 36 in total) [58]. Other studies in
patients with metastatic melanoma treated with BRAF-i alone
or in combination with MEK-i described similar observations
[52, 53, 55–57].
Seremet et al. described 7 patients treated with an immune
checkpoint inhibitor (ICI) in which the course of treatment
was reflected by changes in ctDNA in patients with BRAF-
or NRAS-mutated disease [59]. After initiation of treatment,
the mutant BRAF/NRAS copy level decreased and remained
low or undetectable during complete response and increased
in the case of progressive disease. However, another study in
15 patients reported no difference in ctDNA plasma levels
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after 4 to 8 weeks of ICI therapy in 13 patients compared with
pre-treatment levels although only four patients responded to
treatment (of which two had a 10-fold reduction in ctDNA
levels) [55].
Finally, in 20 patients treated with a combination of
dacarbazine, cisplatin, vinblastine, and tamoxifen, BRAF mu-
tant copies were detected in plasma at baseline and could only
be detected in the plasma of 1 out of 10 responders and in 7
out of 10 non-responders [60]. There were no studies
reporting on the detection of new acquired mutations during
treatment.
The introduction of BRAF-targeted and ICI therapy for
patients with metastatic melanoma has led to an increase in
OS [99]. In patients with irresectable cutaneous melanoma
treated with ICI therapy, a major challenge is the differentia-
tion between “true” progression and pseudo progression (oc-
curring in ~ 10% of patients) on radiological response evalu-
ation. Although other markers, such as serum s100B, LDH,
and the immune-related response criteria, for radiological re-
sponse assessment provide some guidance, no marker is cur-
rently available. In a recent study, plasma samples obtained
from 29 patients with cutaneous melanoma who showed pro-
gression of disease after 12 weeks of ICI therapy, all patients
with pseudo progression (n = 9) had undetectable or > 10-fold
decrease in ctDNA levels compared with pre-treatment levels
[100]. Conversely, of the patients with “true” progression (n =
20), 90% had stable or increasing ctDNA levels compared
with pre-treatment levels after 12 weeks of ICI therapy.
Recent studies have shown an improvement of recurrence-
free survival in patients with stage III melanoma treated with
surgery followed by adjuvant treatment with an ICI [101].
However, ICI therapy bears potential long-lasting risks such as
immune-related adverse events, a proportion of patients will be
treated in vain and therapy costs are high [102, 103]. Therefore,
selection of patients at risk for recurrence is of great importance.
3.3 Colorectal cancer
In colorectal cancer, most studies concern mutations in
KRAS. The detection rate of primary mutations in plasma
was reported in 10 studies which all used PCR-based tech-
niques. The presence of KRAS mutations ranged between 18
and 100% (median 89%).
A higher response rate to chemotherapy and a longer PFS is
described in patients in whom a decrease in ctDNA levels during
therapy was observed compared with patients with stable or in-
creasing ctDNA levels during treatment [69, 77]. Although the
studies showed a trend towards longer survival and better re-
sponse rates in patients with decreasing or undetectable ctDNA
levels upon treatment, no statistically significant association be-
tween ctDNA level, OS, PFS, or radiological response has been
described [61, 63, 67, 70–72, 81]. A decrease in total circulating
cell-free DNA (cfDNA) copies/ml and mutant KRAS/BRAF/
TP53 levels after two cycles of therapy compared with baseline
and a subsequent increase at the time of progression in patients
with CRC were related to treatment response as well as resis-
tance. The decrease after initiation of treatment was larger in
responding than in non-responding patients [66, 74].
Resistance to EGFR-targeted treatment can be caused due
to amplification of the MET proto-oncogene and mutations in
PIK3CA. This METamplification is reported to be detected in
ctDNA before relapse is clinically evident [62, 84]. Mutations
that are newly detected during treatment might reveal the rise
of minor tumor clones that show resistance to the administered
therapy [83].
The emergence of KRAS mutations in KRAS wild-type
patients during anti-EGFR therapy is suggestive for disease
progression and was in some studies detectable in the blood
prior to radiographic detection of progressive disease [68, 75,
78, 79].
Three studies described differences in ctDNA levels in a
total of 29 patients with CRC before and after surgery [64, 65,
82]. In all patients with a complete resection (n = 26), a decline
in ctDNA levels in plasma was observed. Three patients had
tumor recurrence, which occurred simultaneously with recur-
rence of a KRAS mutation in ctDNA. In cases without com-
plete resection (n = 3), ctDNA levels decreased only slightly
or even increased. Additionally, it was observed that in pa-
tients with disease recurrence, an increase of plasma ctDNA
levels occurred before or at the same moment the CEA levels
increased and 2–3 months before radiologic evaluation
showed signs of recurrence [76, 82, 104]. The ctDNA status
at postoperative day 30 could be indicative for disease recur-
rence. Of 94 patients, 10 patients had positive ctDNA samples
at day 30 and had a significantly higher recurrence rate (70%)
compared with patients without detectable ctDNA (11.9%) at
day 30 [105].
Early detection of recurrence will increase the proportion
of patients who are potentially eligible for curative therapy. A
survival benefit from such an approach has been shown in
several meta-analyses [106].
Another study that used sequencing for analysis of ctDNA
described an increase of 34% in the amount of different de-
tectable mutations at the time of progression [80]. These mu-
tations were not detectable at the time of primary disease,
indicating clonal evolution of the disease. Furthermore, NGS
can be used to detect new emerging mutations in the ALK
kinase during treatment with the ALK inhibitor entrectinib
[73]. The emerged mutations are associated with treatment
resistance and warrant treatment with second-generation
ALK inhibitors.
3.4 Breast cancer
TP53-mutations (n = 81), ESR1 (n = 82), PIK3CA-mutations
(n = 53), and AKT-mutations (n = 31) have most frequently
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been assessed to evaluate response to therapy using ctDNA in
patients with breast cancer. As a large variety of mutations in
breast cancer is present, NGS seems more feasible to detect
mutations compared with ddPCR. Six of the 13 included stud-
ies used sequencing for the detection of mutations. The muta-
tion detection rate ranged from 24 to 92% with a median of
50%.
Sequencing of PIK3CA and TP53 performed on ctDNA of
30 patients showed that changes in tumor burden correlated
better with the height of plasma ctDNA levels compared with
CA 15-3 [107]. Detection of TP53 seems feasible to monitor
treatment response as a decrease of TP53 after initiation of
treatment corresponded with response and an increase was a
sign of relapse [91]. Patients with undetectable levels of
ctDNA after one cycle of neoadjuvant chemotherapy had lon-
ger PFS and OS compared with patients in whom ctDNA
remained detectable [85, 94]. In 28 patients with estrogen
receptor positive (ER+) and BCL-2 (estrogen responsive gene
responsible for survival which is overexpressed in 80% of
primary ER+ breast cancer), positive metastatic breast cancer
(MBC) treated with tamoxifen and venetoclax (BCL-2
inhibitor) treatment responses were shown to correlate with
serial changes in ctDNA in plasma. A significant reduction of
both ESR1 and PIK3CA mutations was observed within
28 days of treatment in all patients and it appeared that radio-
logical progression was preceded by a rise in ctDNA [108].
Changing allelic fractions of ctDNA for any given mutation
reflected response to therapy and disease progression in 7
patients [93]. Similar results were described in smaller studies
[86, 90, 95–97].
Murtaza et al. described a patient with metastatic breast
cancer (MBC) in which tumor site-specific mutations were
identified implying heterogeneity of the tumor [90].
Sequencing of ctDNA showed that local progression of one
tumor site coincided with an increase of the circulating abun-
dance of mutations attributed to the lesion at that specific
tumor site. This shows that ctDNA reflects dynamic alter-
ations in size and activity of metastases at various tumor sites.
This is supported by the findings of Page et al. which de-
scribed rising cfDNA concentrations at the moment when
PIK3CA/TP53/ESR1 mutations did not increase or resolved
in the plasma [92]. The rise is probably caused by another
clone that is shedding DNA into the blood that is not detected
with the used ctDNA analysis method.
New mutations have been detected at the moment of pro-
gression which implicate acquired resistance to the treatment
[88, 109]. It was shown that patients with endocrine therapy–
resistant disease and detectable ESR1 mutations in ctDNA
had longer PFS when treated with fulvestrant (n = 45) com-
pared with patients treated with exemestane (n = 18).
Conversely, in patients with wild-type ESR1, no difference
in PFS was observed between both treatment arms. This sug-
gests that ctDNA may direct choice of treatment in patients
with resistant disease. In line with these observations, a meta-
analysis of a combined total of 1530 patients with ER+ MBC
showed shorter PFS for patients with a detectable ESR1 mu-
tation in plasma ctDNA. Plasma ESR1 mutations were asso-
ciated with shorter PFS after aromatase inhibitor–based ther-
apy, but were not predictive of survival in patients treated with
fulvestrant containing therapy [110]. Only three studies report
data in comparison with the time of radiological assessment.
In two of these studies, the ctDNA preceded detection of re-
currence with CT and in one study, ctDNA analysis was as
sensitive as the CT scan [88, 89, 95].
Several studies report the detection of novel mutations in
PIK3CA and ESR1 during therapy in patients with MBC re-
sistant to palbociclib and fulvestrant. These findings could
also guide future treatment strategies to overcome resistance
[87, 111, 112].
4 Future perspectives
4.1 Liquid biopsies to guide targeted therapy
The studies discussed in this review show that various targets
that directly affect treatment decision-making, such as EGFR
mutation in NSCL, BRAF mutation in melanoma, and KRAS
mutation in CRC, can be detected by liquid biopsies.
However, currently, only one liquid biopsy assay to guide
treatment decision-making is FDA approved; the Cobas
EGFR v2, which can be used as a companion diagnostic for
EGFR mutations associated with progression of EGFR
mutation–positive NSCLC [113]. Thus, translation towards
clinical implementation of ctDNA testing and the availability
of appropriate guidelines are urgently needed [114]. For
EGFR mutation testing in NSCLC using plasma samples,
External Quality Assessments (EQA) showed a need for qual-
ity improvements in clinical settings based on a high level of
diagnostic errors [113, 115]. Despite the promising results in
the last few years (this review), disadvantages of current
ctDNA testing include limited sensitivity, restricted clinical
utility, and loss of a direct link between a mutation and a given
lesion [116]. Therefore, ctDNA testing in clinical practice
needs to be further investigated and international consensus
has to be reached on standardized operating procedures [14].
With regard to sensitivity of liquid biopsies, a broad range
sensitivity for mutation detection is seen in the published stud-
ies. This could partly be related to the method of analysis since
not all used methods have the same sensitivity or specificity.
Moreover, the mutations in the reported studies are frequently
solely detected in plasma and not necessarily compared with
mutations detected in the tumor tissue. Therefore, negative
ctDNA results could in fact be true-negative due to absence
of the given mutation. Since negative results can be either a
result of detection limit as well as true-negative results, it is
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questionable whether refrainment from treatment can be based
purely on the absence of a mutation in ctDNA, and tissue-
based analysis will likely remain the golden standard. In con-
trast, positive ctDNA results have shown high specificity in
the different studies and may well be used to guide therapy.
Ideally, either prospective evaluation or retrospective test-
ing of ctDNA analysis and its relation with treatment outcome
from randomized studies is needed to show that the predictive
value of liquid biopsies is comparable with that of the current
gold standard of tissue-based molecular analysis. For the
FDA-approved Cobas EGFR v2, for example, the observed
benefit from erlotinib in the ENSURE trial was comparable
for the patients that had a positive liquid biopsy when com-
pared with tissue-positive patients [117, 118]. In addition, in
the phase III EURTAC trial positive, negative and overall
agreement between liquid biopsy results and tissue-based
analysis for EGFR mutation was very high (94.2%, 97.5%,
and 96.3%, respectively), and it had similar predictive value
for benefit from erlotinib over chemotherapy [119]. Finally,
also in the phase II AURA2 trial, it was shown that T790M
positive patients by liquid biopsy had a high objective re-
sponse rate to osimertinib [120].
Comparable trials showing predictive value of liquid biop-
sies in other tumor types and for other treatments are needed
before liquid biopsies can be considered a replacement for
repeated tumor biopsies. Currently, various liquid biopsy tests
have been granted FDA breakthrough device designation,
among which the FoundationOne Liquid, which captures 70
oncogenes in different tumor types, the Guardant360, which is
a 73-gene panel to guide treatment decision in NSCLC, and
Resolution HRD to determine aberrations in genes associated
with homologous recombination deficiency.
4.2 Additional value of liquid biopsies for response
evaluation
Currently, no liquid biopsy test is approved for response eval-
uation during treatment, but the studies discussed in this re-
view indicate that this is a promising field. Detection of pro-
gressive disease with ctDNA before radiological progression
is reported in twenty-one studies in this review. Since progres-
sion by ctDNA is detected simultaneously with radiological
progression in the majority of the other studies, it could pos-
sibly be used as a substitute for the latter. However, to reliably
use ctDNA in daily practice instead of radiological imaging, a
more consistent sensitivity has to be reached concerning the
detection of predictive and resistant mutations in plasma.
Especially cases where no mutations are detected in the plas-
ma are unreliable and should be tested with more sensitive
assays. Additionally, more studies are needed that correlate
plasma mutations with radiologic data before replacing imag-
ing with ctDNA can be considered. One of the most relevant
settings in which ctDNA quantification may be of additional
value is to differentiate between true progression and
pseudoprogression in patients treated with immune check-
point inhibitors [121]. Current studies are however limited
by low patient numbers, Whether liquid biopsies can ade-
quately result in refrainment from unnecessary treatment,
costs, and potential side effects in patients with true progres-
sion on immunotherapy, while treatment is continued and
eventually results in response in patients with radiologic
pseudoprogression should be addressed in future studies.
4.3 Liquid biopsies to evaluate mutations causing
secondary resistance and tumor heterogeneity
Several studies describe the detection of newmutations during
therapy implying progression on treatment and clonal hetero-
geneity of the tumors. In patients with NSCLC, it has been
demonstrated that mutations which potentially cause therapy
resistance can be detected in ctDNA during treatment with
EGFR TKIs. For example, the well-known T790M mutation
causing acquired resistance to EGFR inhibitors can be detect-
ed in ctDNA of lung cancer patients. Similarly, PIK3CA mu-
tations causing endocrine therapy resistance in breast cancer
patients can be detected in liquid biopsies [122].Thus, ctDNA
could be a promising technique to identify patients at risk for
disease progression and select or adjust systemic therapy ac-
cordingly to improve patient-tailored therapy. Aside from
known resistance mechanisms, liquid biopsies may also aid
to detect new mutations and give insight in other mechanisms
of secondary resistance. Whether these detected mutations
during the course of disease have a role in acquired therapy
resistance and whether they could be targeted to overcome
such treatment resistance must be assessed in larger clinical
studies. In particular, assessment of the association between
the golden standard (i.e., tumor biopsy) and detection of
“new” mutations in plasma is essential.
4.4 Other promising applications of liquid biopsies
Although beyond the scope of this review, there are various
other areas of interest which may show clinical utility of liquid
biopsies. Among these are (i) screening for early-stage cancer,
(ii) to guide neoadjuvant therapy, (iii) as a surveillance tool
after curative treatment, (iv) to assess recurrence risk after
curative treatment and guide adjuvant therapy, and (v) liquid
biopsies from other bodily fluids, such as urine or cerebrospi-
nal fluid [104, 105].
5 Conclusion
The aim of this review was to evaluate the clinical utility of
ctDNA as marker for treatment response and follow-up in
patients with mutation-driven solid malignancies during
Cancer Metastasis Rev
systemic therapy or after surgery. Although multiple studies
show promising results for the utilization of ctDNA measure-
ments in plasma to guide therapy decision-making and assess
response in patients with solid tumors, larger prospective stud-
ies are needed. In order to be utilized as a blood-based marker,
the association between ctDNA, tissue-based molecular anal-
ysis, tumor burden, radiologic response, and survival should
be assessed for different tumor types, mutations, and targeted
therapies individually.
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Highlights - In NSCLC, CRC, breast cancer, and melanoma sequential
ctDNA analysis seems to be informative with regard to clinical disease
status
- Mutations that cause secondary treatment resistance can be detected
by ctDNA analysis during systemic treatment
- There is a lack of prospective randomized studies to reliably
implement ctDNA in clinical practice
- The use of plasma-derived ctDNA is a promising tool for treatment
decision-making
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